2022.03.25
2022_Multifocal Organoid Capturing of Colon Cancer Reveals Pervasive Intratumoral Heterogenous Drug Responses
Multifocal Organoid Capturing of Colon Cancer Reveals Pervasive Intratumoral Heterogenous Drug ResponsesAbstractIntratumor heterogeneity (ITH) stands as one of the main difficulties in the treatment of colorectal cancer (CRC) as it causes the development of resistant clones and leads to heterogeneous drug responses. Here, 12 sets of patient-derived organoids (PDOs) and cell lines (PDCs) isolated from multiple regions of single tumors from 12 patients, capturing ITH by multiregion sampling of individual tumors, are presented. Whole-exome sequencing and RNA sequencing of the 12 sets are performed. The PDOs and PDCs of the 12 sets are also analyzed with a clinically relevant 24-compound library to assess their drug responses. The results reveal unexpectedly widespread subregional heterogeneity among PDOs and PDCs isolated from a single tumor, which is manifested by genetic and transcript-x-xional heterogeneity and strong variance in drug responses, while each PDO still recapitulates the major histologic, genomic, and transcript-x-xomic characteristics of the primary tumor. The data suggest an imminent drawback of single biopsy-originated PDO-based clinical diagnosis in evaluating CRC patient responses. Instead, the results indicate the importance of targeting common somatic driver mutations positioned in the trunk of all tumor subregional clones in parallel with a comprehensive understanding of the molecular ITH of each tumor.
2022.03.25
2021_Establishment of Patient-Derived Pancreatic Cancer Organoids from Endoscopic Ultrasound-Guided Fine-Needle Aspiration Biopsies
Establishment of Patient-Derived Pancreatic Cancer Organoids from Endoscopic Ultrasound-Guided Fine-Needle Aspiration BiopsiesThree-dimensional cultures of human pancreatic cancer tissue also known as "organoids" have largely been developed from surgical specimens. Given that most patients present with locally advanced and/or metastatic disease, such organoids are not representative of the majority of patients. Therefore, we used endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) to collect pancreatic cancer tissues from patients with advanced pancreatic cancer to create organoids, and evaluated their utility in pancreatic cancer research.
2022.03.25
2020_Establishment and characterization of 18 human colorectal cancer cell lines
Establishment and characterization of 18 human colorectal cancer cell lines
2023.02.24
제28차 KCLB Workshop 2023 The 3rd Organoid Culture Techniques Hands-on Workshop
제28차 KCLB Workshop 2023 The 3rd Organoid Culture Techniques Hands-on Workshop 배양세포 클러스터 중앙은행인 한국세포주은행에서 아래와 같이The 3rd Organoid Culture Techniques Hands-on Workshop을 개최합니다.참가자는 10명내외로 모집하며 오가노이드 이론 및 배양교육,실습이 진행됩니다. 참가여부는 개별 통지하며 무료교육으로 진행됩니다.관심있으신 연구자께서는 한국세포주은행 홈페이지 (‘서비스’->‘Hands-on Workshop’)에서 신청하여 주시기 바랍니다.신청기한은 2월24일 ~ 3월 9일 까지입니다.
2023.02.14
** 2023년 3월 분양 일정 안내 **
** 2023년 3월 분양 일정 안내 **3월 1일 수요일 직접분양은 삼일절 진행되지 않으며,3월 2일 목요일 진행되겠습니다.이점 고려하여 분양 신청을 진행해주시고불편하신 사항은 한국세포주은행 카카오채널 및 메일(kclb@kclb.kr)로 문의주시면 감사하겠습니다.감사드립니다.
2023.01.16
27차 KCLB Workshop, Basic Cell Culture Techniques Hands-on Workshop
제27차 KCLB Workshop Basic Cell Culture Techniques Hands-on Workshop배양세포 클러스터 중앙은행인 한국세포주은행에서 아래와 같이 Hands-on Workshop을 개최합니다.참가자는 10명내외로 모집하며 이론및 배양교육,실습이 진행됩니다. 참가여부는 개별 통지하며 무료교육으로 진행됩니다.관심있으신 연구자께서는 한국세포주은행 홈페이지(‘서비스’->‘Hands-on Workshop’)에서 신청하여 주시기 바랍니다.
Korean Cell Line Bank, Korean Cell Line Research Foundation,
101, Daehak-ro, Jongno-gu, Seoul, 03080, Korea
대표자 : 박재갑 | 개인정보보안책임자 : 신영경 | 사업자 등록번호 : 208-82-03887
통신판매업 신고 제2015-서울혜화-0125호 | Tel : 82-2-3668-7915 | Fax : 82-2-742-0021 | Email : kclb@kclb.kr
KCLB (C) is a registered mark of Korean Cell Line Bank. All rights reserved. 1998~2015